These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17613342)

  • 21. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 22. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs.
    Jarernsiripornkul N; Kakaew W; Loalukkana W; Krska J
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):240-5. PubMed ID: 19148880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 28. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Takata GS; Mason W; Taketomo C; Logsdon T; Sharek PJ
    Pediatrics; 2008 Apr; 121(4):e927-35. PubMed ID: 18381521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letter to the Editor. Guillain-Barré Syndrome(GBS) after vaccination reported to the United States Vaccine Adverse Event Reporting System(VAERS) in 2004.
    Haber P; Slade B; Iskander J
    Vaccine; 2007 Nov; 25(48):8101. PubMed ID: 17933441
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trials in vulnerable populations.
    Cook D; Moore-Cox A; Xavier D; Lauzier F; Roberts I
    Clin Trials; 2008; 5(1):61-9. PubMed ID: 18283082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged.
    Wehling M
    J Am Geriatr Soc; 2009 Mar; 57(3):560-1. PubMed ID: 19278399
    [No Abstract]   [Full Text] [Related]  

  • 34. The folly of rewarding silence while hoping for open reporting of adverse medical events--how to realign the rewards.
    Chamberlain N
    N Z Med J; 2008 Sep; 121(1282):58-66. PubMed ID: 18815605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System.
    Woo EJ; Ball R; Landa R; Zimmerman AW; Braun MM;
    Autism; 2007 Jul; 11(4):301-10. PubMed ID: 17656395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospital pharmacists' activities and attitudes regarding the Thai safety monitoring program for new drugs.
    Jarernsiripornkul N; Krska J; Pongmanachai M; Nasritha N
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):837-41. PubMed ID: 19548223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 38. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole.
    Lepik KJ; Levy AR; Sobolev BG; Purssell RA; DeWitt CR; Erhardt GD; Kennedy JR; Daws DE; Brignall JL
    Ann Emerg Med; 2009 Apr; 53(4):439-450.e10. PubMed ID: 18639955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data incompatibility of adverse event reports electronically submitted to the AERS database.
    Glass LM
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):212-3. PubMed ID: 18236510
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.